Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Planchard

Showing results (81-90 of 243) with videos related to

Pageof 25
Sort By:
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 29, 2017
Are we reproducible in measurement of NET liver metastasis?Salma Moalla, Julia Arfi Rouche, Stéphanie Foulon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 11, 2023
Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural MesotheliomaMarco Tagliamento, Massimo Di Maio, Jordi Remon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 24, 2012
Effect of chemotherapy in patients with resected small-cell or large-cell neuroendocrine carcinomaNader Abedallaa, Lise Tremblay, Charlotte Baey, et al.
Cancer Treatment Reviews|September 10, 2023
Local control strategies for management of NSCLC with oligoprogressive diseaseAntoine Mavrikios, Jordi Remon, Clément Quevrin, et al.
Annals of Diagnostic Pathology|May 23, 2020
Non-small cell lung carcinomas with CTNNB1 (beta-catenin) mutations: A clinicopathological study of 26 casesVincent Thomas de Montpréville, Ludovic Lacroix, Etienne Rouleau, et al.
The Lancet. Oncology|September 19, 2017
Dabrafenib plus trametinib in patients with previously untreated BRAF<sup>V600E</sup>-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trialDavid Planchard, Egbert F Smit, Harry J M Groen, et al.
JTO Clinical and Research Reports|January 8, 2026
Gut Dysbiosis as a Potential Guide for Immunotherapy (Dis)Continuation After 2 Years in NSCLC: A Brief ReportAdele Bonato, Claudia Parisi, Priscilla Cascetta, et al.
Lung Cancer (Amsterdam, Netherlands)|April 2, 2021
Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie studyNicolas Epaillard, Jose Carlos Benitez, Teresa Gorria, et al.
Oncotarget|April 28, 2017
Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patientsAngela Boros, Ludovic Lacroix, Benjamin Lacas, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2026
Safety and efficacy of concurrent radiation therapy with amivantamab in patients with advanced EGFR- or MET-altered non-small cell lung cancerDanny Lavigne, Cecile Le Péchoux, Angela Botticella, et al.
Pageof 25

Showing results (81-90 of 243) with videos related to

Sort By:
Pageof 25
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 29, 2017
Are we reproducible in measurement of NET liver metastasis?Salma Moalla, Julia Arfi Rouche, Stéphanie Foulon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 11, 2023
Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural MesotheliomaMarco Tagliamento, Massimo Di Maio, Jordi Remon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 24, 2012
Effect of chemotherapy in patients with resected small-cell or large-cell neuroendocrine carcinomaNader Abedallaa, Lise Tremblay, Charlotte Baey, et al.
Cancer Treatment Reviews|September 10, 2023
Local control strategies for management of NSCLC with oligoprogressive diseaseAntoine Mavrikios, Jordi Remon, Clément Quevrin, et al.
Annals of Diagnostic Pathology|May 23, 2020
Non-small cell lung carcinomas with CTNNB1 (beta-catenin) mutations: A clinicopathological study of 26 casesVincent Thomas de Montpréville, Ludovic Lacroix, Etienne Rouleau, et al.
The Lancet. Oncology|September 19, 2017
Dabrafenib plus trametinib in patients with previously untreated BRAF<sup>V600E</sup>-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trialDavid Planchard, Egbert F Smit, Harry J M Groen, et al.
JTO Clinical and Research Reports|January 8, 2026
Gut Dysbiosis as a Potential Guide for Immunotherapy (Dis)Continuation After 2 Years in NSCLC: A Brief ReportAdele Bonato, Claudia Parisi, Priscilla Cascetta, et al.
Lung Cancer (Amsterdam, Netherlands)|April 2, 2021
Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie studyNicolas Epaillard, Jose Carlos Benitez, Teresa Gorria, et al.
Oncotarget|April 28, 2017
Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patientsAngela Boros, Ludovic Lacroix, Benjamin Lacas, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2026
Safety and efficacy of concurrent radiation therapy with amivantamab in patients with advanced EGFR- or MET-altered non-small cell lung cancerDanny Lavigne, Cecile Le Péchoux, Angela Botticella, et al.
Pageof 25